Investigation of the role of polymorphic loci RS2299941, RS1903858, RS10490920, RS2735343 of the PTEN gene in patients with prostate cancer


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Prostate cancer is a clinically heterogeneous disease, and accurate risk stratification of patients is becoming a key clinical task. This is the most common malignant neoplasm and the leading cause of cancer death in men worldwide. Genomic markers include tools and technologies that can predict the probability of an initial positive biopsy, reduce the number of unnecessary repeated biopsies, identify tumors with low, medium and high risk, classify the degree of disease, as well as predict and monitor the clinical response to intervention. Variants of the PTEN gene are of great interest as genetic markers of the risk of developing prostate malignancies.

Full Text

Restricted Access

About the authors

V. N Pavlov

FGBOU VO Bashkir State Medical University of the Ministry of Health of the Russian Federation

Email: rectorat@bashgmu.ru
Doctor of Medical Sciences, Professor, Academician of the Russian Academy of Sciences, director, Head of Department of Urology with a course IDPO Ufa, Russia

M. V Loginova

FGBOU VO Bashkir State Medical University of the Ministry of Health of the Russian Federation

Email: mariialoginova25@gmail.com
oncologist at the Department of Oncology of Antitumor drug therapy №2, Bashkir State Medical University of the Ministry of Health of the Russia, Clinic of Bashkir State Medical University, Ph.D. student at the Department of Urology with a course of postgraduate education of Bashkir State Medical University Ufa, Russia

E. A Ivanova

FGBUN Institute of biochemistry and genetics of Ufa Federal Research center of RAS

Junior Research Fellow, Institute of Biochemistry and Genetics Ufa, Russia

A. T Mustafin

FGBOU VO Bashkir State Medical University of the Ministry of Health of the Russian Federation

PhD, docent of the Department of Urology with the course of IDPO Ufa, Russia

I. R Gilyazova

FGBUN Institute of biochemistry and genetics of Ufa Federal Research center of RAS

Email: gilyasova_irina@mail.ru
PhD, Senior Research Fellow, Institute of Biochemistry and Genetics Ufa, Russia

References

  1. Saini S. PSA and beyond: Alternative prostate cancer biomarkers. Cell Oncol. 2016;39:97-106. doi: 10.1007/s13402-016-0268-6.
  2. Bray F., Ferlay J., Soerjomataram I., Siegel R.L., Torre L.A., Jemal A. Global Cancer Statistics 2018: GLOBOCAN estimatesof incidence and mortality worldwide for 36 cancersin 185 countries. CA Cancer J Clin. 2018; 68:394424. doi: 10.3322/caac.21492.
  3. Brajtbord J.S., Leapman M.S., Cooperberg M.R The CAPRA score at 10 years: contemporary perspectives and analysis of supporting studies. Eur Urol. 2017;71:705-709. doi: 10.1016/j.eururo.2016.08.065.
  4. Buyyounouski M.K., Choyke P.L., McKenney J.K., Sartor O., Sandler H.M., Amin M.B., Kattan M.W., Lin D.W. Prostate cancer - major changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J Clin. 2017; 67:245-253. doi: 10.3322/caac.21391.
  5. Carter H.B., Albertsen P.C., Barry M.J., Etzioni R., Freedland S.J.,Greene K.L., Holmberg L., Kantoff P., Konety B.R., Murad M.H.et al. Early detection of prostate cancer: AUA Guideline. J Urol. 2013; 190:419-426. doi: 10.1016/j.juro.2013.04.119.
  6. Qi X., Wang Y., Hou J., Huang Y. A single nucleotide polymorphism in HPGD gene is associated with prostate cancer risk. J Cancer. 2017; 8:4083-4086. doi: 10.7150/jca.22025.
  7. Gu X., Zhou L., Lei Chen L., Huiqing Pan H., Zhao R., Guang W. et al. Human Schlafen 5 Inhibits Proliferation and Promotes Apoptosis in Lung Adenocarcinoma via the PTEN/PI3K/AKT/mTOR Pathway. Biomed Res Int. 2021:6628682. doi: 10.1155/2021/6628682.
  8. Wise H.M., Hermida M.A., Leslie N.R. Prostate cancer, PI3K, PTEN and prognosis. Clin Sci. 2017; 131:197-210.doi: 10.1042/CS20160026.
  9. Yoshimoto M., Cunhal. W., Coudry R.A., Fonseca F.P., Torres C.H.,Soares F.A., Squire J.A. FISH analysis of 107 prostate cancers shows that PTEN genomic deletion is associated with poor clinical outcome. Br J Cancer. 2007; 97:678-685. doi: 10.1038/sj.bjc.6603924.
  10. Troyer D.A., Jamaspishvili T., Wei W., Feng Z., Good J. et al. A multicenter study shows PTEN deletion is strongly associated with seminal vesicle involvement and extracapsular extension in localized prostate cancer. Prostate. 2015;75:1206-1215. doi: 10.1002/pros.23003.
  11. Yoshimoto M, Cutz J., Nuin P., Joshua A., Bayani J., Evans A., Zielenska M, Squire J.Interphase FISH analysis of PTEN in histologic sections shows genomic deletions in 68% of primary prostate cancer and 23% of high-grade prostatic intra-epithelial neoplasias. Cancer Genet Cytogenet. 2006;169:128-137. doi: 10.1016/j.cancergencyto.2006.04.003.
  12. Sircar K., Yoshimoto M., Monzon F., Koumakpayi I., Katz R. PTEN genomic deletion is associated with p-Akt and AR signalling in poorer outcome, hormone refractory prostate cancer. J Pathol. 2009; 218:505-513. doi: 10.1002/path.2559.
  13. Wang Y., Dai B. PTEN genomic deletion defines favorable prognostic biomarkers in localized prostate cancer: a systematic review and metaanalysis.Int J ClinExp Med. 2015; 8:5430-5437. PMID: 26131120.
  14. Krohn A., Diedler T., Burkhardt L., Mayer P., De Silva C. et al. Genomic deletion of PTEN is associated with tumor progression and early PSA recurrence in ERG fusion-positive and fusion-negative prostate cancer. Am J Pathol. 2012; 181:401-412. doi: 10.1016/j.ajpath.2012.04.026.
  15. Lotan T.L., Wei W., Ludkovski O., Morais C., Guedes L. et al. Analytic validation of a clinical-grade PTEN immunohistochemistry assay in prostate cancer by comparison with PTEN FISH.Mod Pathol. 2016; 29:904-914. doi: 10.1038/modpathol.2016.88.
  16. Ahearn T.U., Pettersson A., Ebot E., Gerke T., Graff R. et al. A Prospective Investigation of PTEN Loss and ERG Expression in Lethal Prostate Cancer. J Natl Cancer Inst. 2016; 108 (2):djv346. Doi: 10.1093/ jnci/djv346.
  17. Reid A.H., Attard G., Ambroisine L., Fisher G., Kovacs G. et al. Molecular characterisation of ERG, ETV1 and PTEN gene loci identifies patients at low and high risk of death from prostate cancer. Br J Cancer.2010; 102:678-684. doi: 10.1038/sj.bjc.6605554.
  18. Mithal P., Allott E., Gerber L., Reid J., Welbourn W, et al. PTEN loss in biopsy tissue predicts poor clinical outcomes in prostate cancer.International journal of urology: official journal of the Japanese Urological Association. 2014; 21:1209-1214. doi: 10.1111/iju.12571.
  19. Логинова М.В., Павлов В.Н., Гилязова И.Р. Радиомика и радиогеномика рака предстательной железы. Якутский медицинский журнал. 2021;1:101-104. doi: 10.25789/YMJ.2021.73.27
  20. Wang C., Nie H., Li Y., Liu G., Wang X., Xing S., Zhang L., Chen X., Yand C. Y.L. The study of the relation of DNArepair pathway genes SNPs and the sensitivity to radiotherapy and chemotherapy of NSCLC. Sci Rep. 2016; 6:26526. doi: 10.1038/srep26526.
  21. Zhu J., Wang M, He J., Zhu M, Wang J.C., Jin L, Wang X.F., Yang Y.J., Xiang J.Q., Wei Q. Polymorphisms in the AKT1 and AKT2 genes and oesophageal squamous cell carcinoma risk in an Eastern Chinese population. J Cell Mol Med. 2016; 20:666-677. doi: 10.1111/jcmm.12750.
  22. Jang Y., Lu S.A., Chen Z.P., Ma J., Xu C.Q., Zhang C.Z.,Wang J.J. Genetic polymorphisms of CCND1 and PTEN in progression of esophageal squamous carcinoma. Genet Mol Res. 2013;12:6685-6691.doi: 10.4238/2013.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies